Supplementary Table 2. Comparison of patient characteristics between subjects with and without BC360 and all patients in the WSG-ADAPT HER2+/HR- trial.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Patients with BC360 data (n=117) | Patients without BC360 data (n=17) | p-value | All patients in the WSG-ADAPT HER2+/HR- trial(n=134) |
| Age group (years) |  |  |  |  |
| <50 | 42 (35.9) | 5 (29.4) | 0.601 | 47 (35.1) |
| ≥50 | 75 (64.1) | 12 (70.6) |  | 87 (64.9) |
| Menopausal status |  |  |  |  |
| Postmenopausal  | 63 (53.9) | 11 (64.7) | 0.801 | 74 (55.2) |
| Premenopausal  | 49 (41.9) | 6 (35.3) |  | 55 (41.0) |
| Unknown | 5 (4.3) | 0 (0) |  | 5 (3.7) |
| cT, n (%) |  |  |  |  |
| 1 | 46 (39.3) | 7 (41.2) | 0.259 | 53 (39.6) |
| 2 | 63 (53.9) | 7 (41.2) |  | 70 (52.2) |
| 3 | 7 (6) | 3 (17.6) |  | 10 (7.5) |
| 4 | 1 (0.9) | 0 (0) |  | 1 (0.7) |
| cN, n (%) |  |  |  |  |
| 0 | 67 (57.3) | 9 (52.9) | 0.663 | 76 (56.7) |
| 1 | 44 (37.6) | 8 (47.1) |  | 52 (38.8) |
| 2 | 6 (5.1) | 0 (0) |  | 6 (4.5) |
| Grade, n (%) |  |  |  |  |
| 1 | 0 (0) | 1 (5.9) | 0.014 | 1 (0.7) |
| 2 | 9 (7.7) | 3 (17.6) |  | 12 (9.0) |
| 3 | 108 (92.3) | 10 (58.8) |  | 118 (88.1) |
| Unknown | (0) | 3 (17.6) |  | 3 (2.2) |
| HER2 status, local, n (%) |  |  |  |  |
| 1+ | 1 (0.9) | 0 (0) | 0.057 | 1 (0.7) |
| 2+ | 11 (9.4) | 5 () |  | 16 (11.9) |
| 3+ | 105 (84.7) | 12 () |  | 117 (87.3) |
| HER2 status, central, n (%) |  |  |  |  |
| 1+ | 1 (0.9) | 0 (0) | 0.032 | 1 (0.7) |
| 2+ | 3 (2.6) | 3 (17.6) |  | 6 (4.5) |
| 3+ | 113 (96.6) | 12 (70.6) |  | 125 (93.3) |
| Not evaluable | 0 | 2 (11.8) |  | 2 (1.5) |
| PAM50 subtype, n (%) |  |  |  |  |
| Basal | 12 (10.3) | - | - | 12 (9.0) |
| HER2-Enriched | 97 (82.9) | - |  | 97 (72.4) |
| Luminal A | 8 (6.8) | - |  | 8 (59.7) |
| Not evaluated | 0 | 17 (100) |  | 17 (12.7) |
| pCR, n (%) |  |  |  |  |
|  ypT0 ypN0 | 45 (38.5) | 10 (58.8) | 0.124 | 55 (41.0) |
|  ypT0/is ypN0 | 59 (50.4) | 10 (58.8) | 0.562 | 69 (51.5) |